Cargando…

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience

BACKGROUND: Despite the clinical benefit of immune checkpoint inhibitors (ICIs), patients with a viral hepatitis have been excluded from clinical trials because of safety concerns. The purpose of this study was to determine the incidence rate of adverse events (AEs) in patients with viral hepatitis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nardo, Mirella, Yilmaz, Bulent, Nelson, Blessie Elizabeth, Torres, Harrys A, Wang, Lan Sun, Granwehr, Bruno Palma, Song, Juhee, Dalla Pria, Hanna R F, Trinh, Van A, Glitza Oliva, Isabella C, Patel, Sapna P, Tannir, Nizar M, Kaseb, Ahmed Omar, Altan, Mehmet, Lee, Sunyoung S, Miller, Ethan, Zhang, Hao, Stephen, Bettzy A, Naing, Aung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Immuno-Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400154/ https://www.ncbi.nlm.nih.gov/pubmed/36952233 http://dx.doi.org/10.1093/oncolo/oyad039

Ejemplares similares

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
por: Mendoza, Tito, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
por: Tiu, Bruce C, et al.
Publicado: (2023)

PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2019)

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
por: Chang, Elaine, et al.
Publicado: (2021)

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
por: Akamatsu, Hiroaki, et al.
Publicado: (2019)

The Inconsistent and Inadequate Reporting Of Immune‐Related Adverse Events in PD‐1/PD‐L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials
por: Xie, Tong, et al.
Publicado: (2021)

Humoral Immune Response of SARS‐CoV‐2–Infected Patients with Cancer: Influencing Factors and Mechanisms
por: Esperança‐Martins, Miguel, et al.
Publicado: (2021)

Analysis of Real‐World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death‐1 and Programmed Cell Death‐Ligand 1 Inhibitors in Advanced Non‐Small Cell Lung Cancers
por: Ayers, Kristin L., et al.
Publicado: (2021)

Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
por: Alkrekshi, Akram, et al.
Publicado: (2021)

Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer
por: Chen, Ruifeng, et al.
Publicado: (2022)

Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials
por: Wei, Xiao-Li, et al.
Publicado: (2022)

Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers
por: Morris, Van K, et al.
Publicado: (2023)

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
por: Silverstein, Jordyn, et al.
Publicado: (2023)

Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer
por: Wei, Yuanfeng, et al.
Publicado: (2023)

Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center
por: Farha, Natalie, et al.
Publicado: (2023)

Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
por: Mathias, Kristen, et al.
Publicado: (2023)

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses
por: Wheler, Jennifer, et al.
Publicado: (2013)

Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience
por: Tarek, Nidale, et al.
Publicado: (2020)

M.D. Anderson, Oncología /
Publicado: (2000)

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013)

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience
por: Wang, Zhijie, et al.
Publicado: (2016)

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma
por: Nze, Chijioke, et al.
Publicado: (2023)

Neoadjuvant treatment: the MD Anderson experience
por: Hortobagyi, GN
Publicado: (2005)

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
por: Vo, Henry Hiep, et al.
Publicado: (2022)

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
por: Dembla, Vikas, et al.
Publicado: (2018)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
por: Yao, Shuyang, et al.
Publicado: (2022)

M.D. Anderson Cancer Center, oncología quirúrgica /
Publicado: (2005)

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
por: Goldstein, Jennifer B., et al.
Publicado: (2017)

Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID)
por: Williams, Loretta A., et al.
Publicado: (2023)

Obituary Notice of Thomas Anderson, M.D., F.L.S.
Publicado: (1870)

Suicide risk and psychiatric comorbidity in patients with psoriasis
por: Pompili, Maurizio, et al.
Publicado: (2016)

Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials
por: How, Jeffrey A., et al.
Publicado: (2022)

Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience
por: El Hussein, Siba, et al.
Publicado: (2020)

2226. Immune Checkpoint Inhibitors in Solid Tumor Patients with Chronic Hepatitis C Virus Infection: A Prospective Case-Series
por: Hosry, Jeff, et al.
Publicado: (2018)

Ipilimumab: A tale of twists and turns
por: Abhyankar, Dhiraj
Publicado: (2018)

Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy
por: Gupta, Vineet Govinda, et al.
Publicado: (2019)

Long-term safety of etanercept in psoriasis: Retrospective study focused on infections
por: Orsini, Diego, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_43esttgoub7v3glmvt68arht6p